| scholarly article | Q13442814 |
| P50 | author | Betsy C Herold | Q89739748 |
| P2093 | author name string | Kerry Murphy | |
| Susan C. Irvin | |||
| P2860 | cites work | Innate immune defences in the human endometrium | Q24801159 |
| DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells | Q28138968 | ||
| Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium | Q28191288 | ||
| Vaginal microbiome of reproductive-age women | Q28284755 | ||
| The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells | Q28302792 | ||
| Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women | Q31112477 | ||
| Molecular identification of bacteria associated with bacterial vaginosis. | Q33226498 | ||
| Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid | Q33227608 | ||
| Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies | Q33627673 | ||
| Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection | Q33779655 | ||
| Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans | Q33782608 | ||
| A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. | Q33808638 | ||
| Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins | Q41088834 | ||
| Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women. | Q42906456 | ||
| Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users | Q43405440 | ||
| Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression | Q44226643 | ||
| Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. | Q44442528 | ||
| The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy | Q44865495 | ||
| Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission | Q45407660 | ||
| Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization | Q45477038 | ||
| Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition | Q45746359 | ||
| Progesterone implants enhance SIV vaginal transmission and early virus load | Q45767734 | ||
| High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. | Q46034053 | ||
| The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression | Q46162481 | ||
| Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells | Q46771610 | ||
| PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. | Q51065292 | ||
| Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. | Q51302460 | ||
| Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. | Q53880710 | ||
| Variations in the levels of secretory component in human uterine fluid during the menstrual cycle | Q71305129 | ||
| The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera | Q73054855 | ||
| Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium | Q74228757 | ||
| Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women | Q77626176 | ||
| Synergistic copathogens--HIV-1 and HSV-2 | Q79808081 | ||
| Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques | Q33827820 | ||
| Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages | Q33845503 | ||
| Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines | Q33943791 | ||
| Progesterone increases susceptibility and decreases immune responses to genital herpes infection | Q34186763 | ||
| Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. | Q34317930 | ||
| Pharmacokinetics of depot medroxyprogesterone acetate contraception. | Q34390234 | ||
| Cervicovaginal Shedding of HIV Type 1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota | Q34553877 | ||
| Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection | Q34693822 | ||
| Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia | Q35068652 | ||
| Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. | Q35565782 | ||
| Bacterial vaginosis: Etiology and modalities of treatment-A brief note. | Q35646141 | ||
| Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study | Q35699938 | ||
| CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women | Q35784816 | ||
| Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection | Q36095139 | ||
| Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission | Q36230178 | ||
| Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women | Q36509620 | ||
| Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy | Q36559887 | ||
| Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms | Q36628484 | ||
| Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues | Q36634806 | ||
| Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk | Q36888158 | ||
| Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism | Q36898823 | ||
| Changes in the soluble mucosal immune environment during genital herpes outbreaks | Q36937188 | ||
| In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa | Q36955176 | ||
| Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies | Q37211585 | ||
| Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition | Q37295563 | ||
| Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections | Q37334286 | ||
| Innate immunity in the vagina (part I): estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells | Q37334315 | ||
| Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. | Q37334338 | ||
| Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study | Q37873613 | ||
| Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. | Q38058410 | ||
| Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission | Q38105449 | ||
| Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. | Q39473447 | ||
| Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection | Q40360352 | ||
| Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus | Q40368653 | ||
| Syndecan captures, protects, and transmits HIV to T lymphocytes | Q40677051 | ||
| Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells | Q40978781 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | birth control | Q122224 |
| P304 | page(s) | 228-35 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | American Journal of Reproductive Immunology | Q15761228 |
| P1476 | title | Research gaps in defining the biological link between HIV risk and hormonal contraception | |
| P478 | volume | 72 |
| Q40632328 | A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk |
| Q92496129 | Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age |
| Q41074827 | Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques |
| Q47731889 | Bacterial vaginosis modifies the association between hormonal contraception and HIV acquisition |
| Q91973442 | Crosstalk Between Female Gonadal Hormones and Vaginal Microbiota Across Various Phases of Women's Gynecological Lifecycle |
| Q36921893 | Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract |
| Q38851686 | Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial |
| Q37651577 | Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium |
| Q30387557 | Factors Driving the HIV Epidemic in Southern Africa |
| Q34117651 | Gonadal function and reproductive health in women with human immunodeficiency virus infection |
| Q64133816 | HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa |
| Q47198102 | Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms |
| Q30660068 | Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies |
| Q50956725 | Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply. |
| Q36828511 | Intravaginal practices among HIV-negative female sex workers along the US-Mexico border and their implications for emerging HIV prevention interventions |
| Q49838895 | Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV? |
| Q36068904 | Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women |
| Q40515915 | Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals? |
| Q37280240 | Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection |
| Q35784803 | Medroxyprogesterone acetate impairs human dendritic cell activation and function |
| Q35208283 | Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk |
| Q89664038 | Norethisterone Enanthate Increases Mouse Susceptibility to Genital Infection with Herpes Simplex Virus Type 2 and HIV Type 1 |
| Q39237289 | Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites |
| Q35172396 | Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression. |
| Q36284595 | Relationship of Estimated SHIV Acquisition Time Points During the Menstrual Cycle and Thinning of Vaginal Epithelial Layers in Pigtail Macaques |
| Q40047233 | Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV-1 in the female genital tract. |
| Q39207555 | Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada |
| Q38157367 | Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques. |
Search more.